Comprehensive Review: Disseminated Intravascular Coagulation (DIC) and Vitamin K Deficiency in Children
DISSEMINATED INTRAVASCULAR COAGULATION (DIC)
Brief Explanation & Pathophysiology
DIC is an acquired, life-threatening intravascular disorder characterized by systemic coagulation activation, dysregulated fibrinolysis, and endothelial injury, resulting in widespread microthrombosis that progresses from a potentially asymptomatic early phase to an advanced phase with hemorrhage and/or organ dysfunction 1.
The pathophysiology involves four key phases 2:
- Initiation phase: Cellular damage releases histones and damage-associated molecular patterns (DAMPs) that trigger innate immune-mediated coagulation activation 2
- Amplification phase: Excessive thrombin generation leads to platelet and fibrinogen activation while simultaneously depleting clotting factors 3
- Propagation phase: Anticoagulation pathways (protein C, protein S, antithrombin) become impaired 2
- Reinforcement phase: Persistent fibrinolysis suppression results in widespread microvascular thrombosis, followed by hemorrhagic consumption coagulopathy and multiple organ dysfunction syndrome 2
The haemostatic system in neonates and young children differs significantly from adults (developmental coagulopathy), placing them at greater risk for DIC when additional body systems are compromised 4.
Epidemiology
- DIC is not uncommon in children and is associated with significant morbidity and mortality 5, 6
- Neonates (0-1 month old) are at particularly high risk due to developmental coagulopathy 4
- The condition commonly accompanies life-threatening illnesses in pediatric patients 7
- Specific prevalence data in pediatric populations remain limited due to diagnostic challenges and variable presentation 5
Classifications/Subtypes
DIC can be classified by clinical presentation 6, 2:
- Early-phase (pre-DIC): Potentially asymptomatic with laboratory evidence of coagulation activation but without overt bleeding or thrombosis 1
- Overt DIC (late-phase): Characterized by two dominant clinical patterns:
- Sepsis-associated DIC (most common in children)
- Trauma-associated DIC
- Malignancy-associated DIC
- Obstetric complications-associated DIC (adolescents)
Differential Diagnosis
Critical distinction: Vitamin K deficiency can mimic DIC and is frequently misdiagnosed as DIC 8.
Key differentials include:
- Vitamin K deficiency: Prolonged PT/aPTT with normal platelet count and fibrinogen; no D-dimer elevation; corrects rapidly with vitamin K administration 9, 8
- Liver disease/cirrhotic coagulopathy: Low synthesis of clotting factors but typically preserved fibrinogen; may have concurrent low-grade DIC 10
- Thrombotic thrombocytopenic purpura (TTP): Thrombocytopenia with microangiopathic hemolytic anemia but normal coagulation times 5
- Hemolytic uremic syndrome (HUS): Similar to TTP with renal involvement 5
- Primary fibrinolysis: Isolated hyperfibrinolysis without consumption of clotting factors 5
- Massive transfusion coagulopathy: Dilutional coagulopathy without systemic coagulation activation 5
Detailed Causes & High-Risk Factors
Primary causes in children 5, 7, 3:
Infectious causes (most common):
- Gram-negative septicemia (endotoxin-mediated) 9
- Gram-positive septicemia
- Viral infections (severe influenza, COVID-19, hemorrhagic fever viruses)
- Fungal sepsis
- Parasitic infections (malaria)
Trauma-related:
- Severe head injury
- Multiple trauma with tissue injury
- Burns
- Heat stroke
Malignancies:
- Acute promyelocytic leukemia (APL) - highest risk
- Other acute leukemias
- Solid tumors with extensive necrosis
- Neuroblastoma
Neonatal-specific causes 4:
- Perinatal asphyxia
- Respiratory distress syndrome
- Necrotizing enterocolitis
- Neonatal sepsis
- Severe hemolytic disease of the newborn
Vascular/cardiac:
- Giant hemangiomas (Kasabach-Merritt syndrome)
- Large vascular malformations
- Aortic aneurysm
Immunologic:
- Severe transfusion reactions
- Transplant rejection
- Severe allergic reactions
Toxic/metabolic:
- Snake envenomation
- Drug reactions
- Severe acidosis
- Hypothermia
- Age <1 month (developmental coagulopathy)
- Pre-existing liver disease
- Malnutrition
- Immunocompromised state
- Central venous catheters
- Recent major surgery
Complications
Hemorrhagic complications 7, 2:
- Oozing from venipuncture sites, surgical wounds, mucous membranes
- Gastrointestinal bleeding
- Intracranial hemorrhage (particularly high risk in neonates)
- Pulmonary hemorrhage
- Requirement for massive transfusion
Thrombotic complications 2:
- Acute kidney injury/renal failure
- Acute respiratory distress syndrome (ARDS)
- Hepatic dysfunction
- Cardiac dysfunction
- Neurological impairment from cerebral microthrombosis
- Peripheral gangrene/acral necrosis
- Purpura fulminans
Long-term sequelae:
- Chronic kidney disease
- Neurodevelopmental impairment (especially neonates with ICH)
- Limb amputation
- Death (mortality ranges 30-80% depending on underlying cause and severity) 7
Typical Presentations
Clinical presentation is highly variable and depends on the phase and underlying etiology 6.
Early-phase DIC 1:
- May be asymptomatic
- Subtle signs: petechiae, mild oozing from IV sites
- Laboratory abnormalities precede clinical manifestations
- Spontaneous bleeding from multiple sites simultaneously
- Persistent oozing from venipuncture sites, surgical wounds, endotracheal tubes
- Ecchymoses and petechiae
- Mucosal bleeding (epistaxis, gingival bleeding)
- Hematuria
- Gastrointestinal bleeding (hematemesis, melena)
Thrombotic DIC 2:
- Signs of organ dysfunction: oliguria/anuria, altered mental status, respiratory distress
- Acrocyanosis or peripheral gangrene
- Purpura fulminans (large ecchymotic areas with central necrosis)
Neonatal presentation 4:
- Generalized bleeding tendency
- Umbilical stump bleeding
- Cephalohematoma expansion
- Intraventricular hemorrhage
- Respiratory distress
- Shock
Detailed Approach to History
Underlying condition assessment 5, 7:
- Onset and duration of current illness
- Documented or suspected infection (fever, source, culture results)
- Recent trauma or surgery (timing, extent)
- Known malignancy (type, treatment status)
- Neonatal history: birth asphyxia, prematurity, respiratory distress, feeding intolerance
Bleeding history 5:
- Onset: acute vs. gradual
- Sites: single vs. multiple simultaneous sites
- Severity: oozing vs. frank hemorrhage
- Provoked (post-procedure) vs. spontaneous
- Response to local measures
Thrombotic symptoms 5:
- Decreased urine output
- Respiratory distress
- Altered consciousness
- Skin changes (acrocyanosis, purpura)
Medication history 8:
- Antibiotics (can contribute to vitamin K deficiency)
- Anticoagulants
- Chemotherapy
- Recent blood product administration
Nutritional history 8:
- Adequacy of oral intake
- Duration of NPO status
- Total parenteral nutrition without vitamin K supplementation
- Malabsorption symptoms
Family history 5:
- Inherited bleeding disorders
- Thrombophilia
- Consanguinity
Detailed Physical Examination
- Vital signs: tachycardia, hypotension, fever, tachypnea (signs of shock or sepsis)
- Level of consciousness: alert vs. lethargic vs. unresponsive
- Growth parameters in chronic cases
Skin examination 5:
- Petechiae: distribution (generalized vs. localized), density
- Purpura: size, location, progression
- Ecchymoses: spontaneous vs. at pressure points
- Purpura fulminans: large ecchymotic areas with central necrosis and bullae formation
- Acrocyanosis: discoloration of fingers, toes, nose, ears
- Surgical/IV sites: active oozing, hematoma formation
Mucous membranes 5:
- Gingival bleeding
- Oral petechiae or blood blisters
- Conjunctival hemorrhage
Cardiovascular 2:
- Signs of shock: weak pulses, prolonged capillary refill (>3 seconds), cool extremities
- Cardiac dysfunction: gallop rhythm, hepatomegaly
Respiratory 2:
- Respiratory distress: tachypnea, retractions, grunting
- Hemoptysis
- Decreased breath sounds (pulmonary hemorrhage)
Abdominal 5:
- Hepatosplenomegaly (underlying malignancy, sepsis)
- Abdominal distension (necrotizing enterocolitis in neonates)
- Signs of gastrointestinal bleeding: hematemesis, melena, hematochezia
Neurological 4:
- Altered mental status
- Focal neurological deficits
- Seizures
- In neonates: bulging fontanelle, abnormal tone
Genitourinary 5:
- Hematuria (gross vs. microscopic)
- Oliguria/anuria
Diagnostic Investigations
There is no single gold standard test for DIC; diagnosis requires a combination of clinical context and laboratory findings 6.
Initial Panel (Stat Laboratory Tests) 5, 7, 1:
- Complete blood count with differential and blood smear
- Prothrombin time (PT)
- Activated partial thromboplastin time (aPTT)
- Fibrinogen level
- D-dimer or fibrin degradation products (FDP)
- Platelet count
Comprehensive Panel 5, 7:
- Peripheral blood smear: schistocytes (microangiopathic hemolytic anemia)
- Antithrombin (AT) level
- Protein C and Protein S levels
- Thrombin-antithrombin complexes (TAT)
- Prothrombin fragment 1+2 (F1+2)
- Soluble fibrin monomer
- Factor assays (V, VIII) if diagnosis unclear
- Lactate dehydrogenase (LDH) and indirect bilirubin (hemolysis markers)
- Renal function: creatinine, BUN
- Liver function tests: ALT, AST, bilirubin, albumin
- Arterial blood gas: assess acidosis, lactate
- Blood cultures (if sepsis suspected)
- Coagulation factor assays to differentiate from vitamin K deficiency if needed
Expected Abnormal Results in DIC 5, 7, 1:
Early-phase DIC:
- Platelet count: mild thrombocytopenia or high-normal
- PT/aPTT: normal or mildly prolonged
- Fibrinogen: normal or elevated (acute phase reactant)
- D-dimer/FDP: elevated
- AT, Protein C: decreased
Overt DIC:
- Platelet count: <100,000/μL (often <50,000/μL)
- PT: prolonged (>3 seconds above control or INR >1.4)
- aPTT: prolonged
- Fibrinogen: <100 mg/dL (severe cases <50 mg/dL)
- D-dimer/FDP: markedly elevated (>5× upper limit of normal)
- Blood smear: schistocytes, fragmented RBCs
- AT level: <70% of normal
- Protein C/S: decreased
Serial monitoring (every 6-12 hours in acute phase) is essential as DIC is a dynamic process 5.
Diagnostic Scoring Systems 7, 1:
ISTH Overt DIC Score (2001, updated 2025) - requires underlying disorder known to cause DIC:
- Platelet count: >100,000 (0 points), 50,000-100,000 (1 point), <50,000 (2 points)
- D-dimer/FDP elevation: no increase (0), moderate increase (2), strong increase (3)
- PT prolongation: <3 sec (0), 3-6 sec (1), >6 sec (2)
- Fibrinogen: >100 mg/dL (0), <100 mg/dL (1)
Score ≥5 indicates overt DIC 1
Note: Pediatric-specific validation of scoring systems is limited; clinical judgment must guide interpretation in children, especially neonates 7.
Initial Management
The cornerstone of DIC management is aggressive treatment of the underlying condition 5, 7, 2.
Immediate Priorities 5, 7:
Treat underlying cause aggressively:
- Sepsis: broad-spectrum antibiotics, source control, hemodynamic support
- Trauma: surgical intervention, damage control
- Malignancy: chemotherapy (APL: all-trans retinoic acid + arsenic trioxide)
- Obstetric: delivery of fetus/placenta
Hemodynamic stabilization 7:
- Fluid resuscitation: isotonic crystalloids 20 mL/kg boluses
- Vasopressor support if fluid-refractory shock: norepinephrine 0.05-2 mcg/kg/min
- Maintain adequate tissue perfusion
Respiratory support 7:
- Supplemental oxygen to maintain SpO₂ >92%
- Mechanical ventilation if respiratory failure
Blood Component Replacement Therapy 5, 7:
Indications for transfusion:
- Active bleeding: transfuse if platelets <50,000/μL
- High bleeding risk (invasive procedures, CNS involvement): maintain >50,000/μL
- No active bleeding: consider if <10,000-20,000/μL
- Dose: 10-15 mL/kg of platelet concentrate or 1 unit/10 kg body weight
- Target: increase of 50,000-100,000/μL
Fresh frozen plasma (FFP) 5, 7:
- Indications: active bleeding with prolonged PT/aPTT (>1.5× control) or before invasive procedures
- Dose: 10-15 mL/kg (typically 15 mL/kg)
- Target: PT/aPTT <1.5× control
- Frequency: may need to repeat every 6-12 hours
- Indications: fibrinogen <100 mg/dL with active bleeding or <50 mg/dL
- Dose: 1 unit/5-10 kg or 5-10 mL/kg
- Target: fibrinogen >100 mg/dL (ideally >150 mg/dL)
- Each unit contains approximately 200-250 mg fibrinogen
Packed red blood cells (PRBCs) 7:
- Indications: hemoglobin <7 g/dL or symptomatic anemia
- Dose: 10-15 mL/kg
- Target: hemoglobin 7-9 g/dL (higher if ongoing bleeding or hemodynamic instability)
Important: Avoid prophylactic transfusions in non-bleeding patients without procedures planned, as this may fuel the coagulation cascade 5.
Anticoagulant Therapy 5, 7:
Controversial and not routinely recommended in children 7.
Potential indications (case-by-case basis):
- Predominant thrombotic manifestations (purpura fulminans, acral ischemia)
- Chronic DIC with thrombosis
- Failure of supportive care alone
Unfractionated heparin (UFH) 5:
- Dose: 5-10 units/kg/hour continuous infusion (no bolus)
- Monitoring: aPTT 1.5-2× baseline or anti-Xa 0.3-0.7 IU/mL
- Contraindications: active CNS bleeding, recent neurosurgery, platelet count <20,000/μL
Low molecular weight heparin (LMWH) 5:
- Enoxaparin dose: 1 mg/kg subcutaneous every 12 hours (infants <2 months may require 1.5 mg/kg every 12 hours)
- Monitoring: anti-Xa level 0.5-1.0 IU/mL (4 hours post-dose)
Antithrombin (AT) concentrate 7:
- Limited evidence in children; some studies suggest benefit in sepsis-associated DIC
- Dose: 50-100 units/kg IV loading dose, then 50 units/kg every 12-24 hours
- Target: AT activity >80%
- Not routinely recommended due to lack of pediatric data and high cost
Recombinant thrombomodulin (rTM) 7:
- Emerging therapy with some evidence in adults; pediatric data very limited
- Dose: 0.06 mg/kg/day IV for 6 days (based on adult studies)
- Not FDA-approved in United States; available in Japan
Protein C concentrate 7:
- Indications: purpura fulminans with severe protein C deficiency
- Dose: 100-120 units/kg loading dose, then 60-80 units/kg every 6-12 hours
- Target: protein C activity >25%
Antifibrinolytic Therapy 11, 5:
Generally contraindicated in DIC due to risk of worsening thrombosis.
Rare exception: hyperfibrinolysis-dominant DIC (very elevated D-dimer with low fibrinogen but minimal thrombocytopenia)
- Tranexamic acid: 10 mg/kg IV loading dose, then 10 mg/kg every 8 hours
- Only use with concurrent heparin to prevent thrombosis
Vitamin K Administration 11:
Always administer vitamin K to exclude or treat concurrent vitamin K deficiency 8.
- Dose:
- Neonates: 1 mg IV/IM/subcutaneous
- Infants and children: 1-5 mg IV/IM/subcutaneous (0.5-1 mg/kg, max 10 mg)
- Route: IV preferred in acute bleeding (slow infusion over 20-30 minutes to avoid anaphylaxis)
- Response: PT should improve within 6-12 hours if vitamin K deficiency is contributing
Ongoing Management
Continuous reassessment is critical 5, 7:
- Monitor vital signs: every 1-4 hours depending on stability
- Serial laboratory testing: CBC, PT/aPTT, fibrinogen, D-dimer every 6-12 hours initially, then daily as stabilizes
- Assess bleeding sites: document new bleeding or progression
- Organ function monitoring: daily creatinine, liver enzymes, arterial blood gas
- Fluid balance: strict intake/output monitoring
Adjust blood product support 5:
- Continue transfusions as needed based on laboratory values and clinical bleeding
- Wean transfusion support as DIC resolves (improving platelet count, fibrinogen, decreasing D-dimer)
Nutritional support 7:
- Enteral nutrition as tolerated (may need to delay if gastrointestinal bleeding)
- Parenteral nutrition if prolonged NPO status
- Ensure vitamin K supplementation in all patients on prolonged antibiotics or inadequate oral intake 8
Infection control 5:
- Continue antibiotics for full course
- Remove/replace infected catheters
- Source control of any abscesses or necrotic tissue
Thromboprophylaxis after resolution 5:
- Consider prophylactic anticoagulation once platelet count >50,000/μL and no active bleeding
- Especially important in patients with central venous catheters or prolonged immobility
Prognosis & Follow-Up
Prognosis depends primarily on the underlying condition and rapidity of treatment 7, 6.
Mortality rates 7:
- Overall pediatric DIC mortality: 30-50%
- Sepsis-associated DIC: 40-80%
- Trauma-associated DIC: 20-40%
- Malignancy-associated DIC: variable (APL with treatment: <10%; other malignancies: 50-70%)
- Neonatal DIC: 30-60%
Favorable prognostic factors 7:
- Early recognition and treatment
- Reversible underlying cause
- Absence of multi-organ failure
- Preserved renal function
- Delayed diagnosis
- Multi-organ dysfunction syndrome
- Severe thrombocytopenia (<20,000/μL)
- Very low fibrinogen (<50 mg/dL)
- Intracranial hemorrhage
- Underlying malignancy
Follow-up recommendations 5:
Short-term (first 3 months):
- Weekly CBC, PT/aPTT, fibrinogen for first 2-4 weeks after resolution
- Monitor for recurrence if underlying condition persists
- Assess for complications: renal function (creatinine, urinalysis), liver function
- Neurodevelopmental assessment in neonates with ICH
Long-term:
- Monitor for chronic kidney disease (annual creatinine, urinalysis)
- Neurodevelopmental follow-up in survivors of neonatal DIC with CNS involvement
- Assess for limb function if peripheral ischemia occurred
- Psychological support for patients and families
Prevention
Primary prevention focuses on preventing or promptly treating conditions that cause DIC 5, 7:
Infection prevention:
- Hand hygiene protocols
- Aseptic technique for invasive procedures
- Appropriate catheter care and timely removal
- Vaccination (pneumococcal, meningococcal, influenza)
Early recognition and treatment of sepsis 5:
- Prompt administration of antibiotics within 1 hour of recognition
- Aggressive hemodynamic support
- Source control
Trauma management:
- Damage control surgery principles
- Early hemorrhage control
- Avoid hypothermia, acidosis, coagulopathy (lethal triad)
Neonatal care 4:
- Prevent perinatal asphyxia: appropriate obstetric care, neonatal resuscitation
- Early recognition and treatment of necrotizing enterocolitis
- Prompt treatment of neonatal sepsis
Vitamin K prophylaxis 12, 13, 12:
- All newborns should receive vitamin K at birth: 1 mg IM (preferred) or 2 mg oral at birth, 4-6 days, and 4-6 weeks 12
- Patients on prolonged antibiotics or inadequate nutrition: prophylactic vitamin K 1-5 mg weekly 8
- Patients on parenteral nutrition: ensure vitamin K supplementation (10 mcg/kg/day for infants, 200 mcg/day for older children) 13
Malignancy management:
- Early initiation of chemotherapy in APL (all-trans retinoic acid)
- Prophylactic transfusion support during high-risk procedures
Monitoring high-risk patients 5:
- Serial coagulation studies in critically ill children
- Early intervention at first signs of coagulation abnormalities
VITAMIN K DEFICIENCY
Brief Explanation & Pathophysiology
Vitamin K is essential for the carboxylation of coagulation factors II, VII, IX, X, and proteins C and S 13. Without adequate vitamin K, these factors are produced in an undercarboxylated (non-functional) form, leading to impaired coagulation.
Mechanism 13:
- Vitamin K acts as a cofactor for γ-glutamyl carboxylase, which converts glutamic acid residues on vitamin K-dependent proteins to γ-carboxyglutamic acid
- This carboxylation is essential for calcium binding and subsequent activation of the coagulation cascade
- Vitamin K is recycled through the vitamin K epoxide reductase cycle; this cycle can be interrupted by warfarin or certain antibiotics
Vitamin K does not cross the placenta, and coagulation factors are not transferred transplacentally, making newborns particularly vulnerable 13.
Epidemiology
Vitamin K deficiency bleeding (VKDB) in newborns 12:
- Without prophylaxis: incidence of classic VKDB is 0.25-1.7% of newborns
- With IM prophylaxis: incidence reduced to <0.01%
- Late VKDB (2-12 weeks): 4.4-10.5 per 100,000 births without prophylaxis; <0.1 per 100,000 with IM prophylaxis
Older children and hospitalized patients 8:
- Vitamin K deficiency is underrecognized in critically ill hospitalized patients
- One study found 42 hospitalized patients with vitamin K deficiency, most misdiagnosed as DIC 8
- Contributing factors: inadequate diet, malabsorption, antibiotic therapy, lack of prophylactic supplementation
Classifications/Subtypes
Vitamin K deficiency bleeding (VKDB) in newborns 12:
Early VKDB:
- Timing: first 24 hours of life
- Cause: maternal medications that interfere with vitamin K metabolism (anticonvulsants, warfarin, rifampin, isoniazid)
- Presentation: cephalohematoma, intracranial hemorrhage, umbilical bleeding
- Incidence: rare with maternal medication use
Classic VKDB:
- Timing: 1-7 days of life
- Cause: inadequate vitamin K stores, insufficient breast milk vitamin K, no prophylaxis
- Presentation: gastrointestinal bleeding, umbilical stump bleeding, skin ecchymoses, post-circumcision bleeding
- Incidence: 0.25-1.7% without prophylaxis
Late VKDB:
- Timing: 2-12 weeks of life (can occur up to 6 months)
- Cause: exclusively breastfed infants without prophylaxis, malabsorption (cholestasis, cystic fibrosis, celiac disease)
- Presentation: intracranial hemorrhage (30-50% of cases), gastrointestinal bleeding, skin ecchymoses
- Incidence: 4.4-10.5 per 100,000 births without prophylaxis
- Highest risk: exclusively breastfed infants with unrecognized cholestasis
Acquired vitamin K deficiency in older children 8:
- Nutritional: prolonged inadequate intake, malabsorption (cystic fibrosis, celiac disease, short bowel syndrome, cholestatic liver disease)
- Antibiotic-associated: broad-spectrum antibiotics suppress gut flora that produce vitamin K
- Medication-induced: warfarin, certain antibiotics (cephalosporins), anticonvulsants
Differential Diagnosis
Vitamin K deficiency must be distinguished from other causes of prolonged PT/aPTT 9, 8:
- Disseminated intravascular coagulation (DIC): thrombocytopenia, low fibrinogen, elevated D-dimer; vitamin K deficiency has normal platelets and fibrinogen 9, 8
- Liver disease: low albumin, elevated bilirubin, transaminases; may have concurrent vitamin K deficiency 10
- Hemophilia A or B: isolated prolonged aPTT with normal PT; factor VIII or IX deficiency
- Factor VII deficiency: isolated prolonged PT with normal aPTT
- Warfarin overdose: history of warfarin use; similar laboratory pattern to vitamin K deficiency
- Malabsorption syndromes: may have concurrent fat-soluble vitamin deficiencies (A, D, E)
Key distinguishing features of vitamin K deficiency 9, 8:
- Prolonged PT and aPTT
- Normal platelet count
- Normal fibrinogen
- Normal or low D-dimer (not elevated as in DIC)
- Rapid correction with vitamin K (PT improves within 6-12 hours)
- Elevated PIVKA-II (proteins induced by vitamin K absence) if measured 13
Detailed Causes & High-Risk Factors
Neonatal/infant causes 12, 13, 12:
Inadequate stores at birth:
- Vitamin K does not cross placenta efficiently
- Newborns have 30-60% of adult vitamin K levels
- Premature infants have even lower stores
Inadequate intake:
- Breast milk is low in vitamin K (1-4 mcg/L vs. 50-60 mcg/L in formula)
- Exclusively breastfed infants without supplementation
- Delayed or inadequate feeding
Maternal medications (early VKDB):
- Anticonvulsants: phenytoin, phenobarbital, carbamazepine
- Warfarin
- Rifampin, isoniazid
- Cephalosporins
Malabsorption (late VKDB):
- Biliary atresia or other cholestatic conditions
- Cystic fibrosis
- α1-antitrypsin deficiency
- Celiac disease
- Short bowel syndrome
Older children and hospitalized patients 8:
Inadequate intake:
- Prolonged NPO status (>5-7 days without supplementation)
- Inadequate enteral or parenteral nutrition
- Eating disorders
Malabsorption:
- Inflammatory bowel disease
- Celiac disease
- Cystic fibrosis
- Short bowel syndrome
- Chronic diarrhea
- Cholestatic liver disease
- Broad-spectrum antibiotics suppress vitamin K-producing gut flora
- Cephalosporins (especially cefoperazone) directly inhibit vitamin K epoxide reductase
- Duration >7-10 days increases risk
Liver disease:
- Impaired bile acid synthesis reduces fat-soluble vitamin absorption
- Decreased synthesis of vitamin K-dependent factors
Other medications:
- Warfarin (intentional anticoagulation)
- Salicylates (high doses)
- Mineral oil (impairs absorption)
High-risk factors 8:
- Critically ill hospitalized patients
- Recent major surgery
- Renal insufficiency
- Malnutrition
- Pregnancy (adolescents)
- Combination of inadequate intake + antibiotics
Complications
Hemorrhagic complications 12:
Neonatal/infant:
- Intracranial hemorrhage: most serious complication of late VKDB; occurs in 30-50% of late VKDB cases
- Subdural, subarachnoid, intraparenchymal, or intraventricular hemorrhage
- High mortality (up to 20%) and morbidity (30-50% have permanent neurological sequelae)
- Gastrointestinal bleeding: hematemesis, melena, hematochezia
- Umbilical stump bleeding
- Post-circumcision bleeding
- Cephalohematoma (may expand)
- Skin ecchymoses and petechiae
Older children 8:
- Gastrointestinal bleeding: most common site in hospitalized patients
- Hematuria
- Epistaxis
- Gingival bleeding
- Intramuscular hematomas
- Post-surgical bleeding
- Intracranial hemorrhage (rare but catastrophic)
Mortality and morbidity 8:
- In one series of 42 hospitalized patients with vitamin K deficiency, 34% required RBC transfusions and 24% ultimately died (though not all deaths directly attributable to bleeding) 8
Typical Presentations
Early VKDB (first 24 hours) 12:
- Cephalohematoma (may be large and expanding)
- Intracranial hemorrhage (presents with lethargy, seizures, bulging fontanelle, apnea)
- Umbilical bleeding
- Gastrointestinal bleeding
- History of maternal medication use (anticonvulsants, warfarin)
Classic VKDB (1-7 days) 12:
- Gastrointestinal bleeding (hematemesis, melena) - most common
- Umbilical stump oozing or frank bleeding
- Skin ecchymoses (often at pressure points or trauma sites)
- Post-circumcision bleeding
- Nasal bleeding
- Exclusively breastfed infant without vitamin K prophylaxis
Late VKDB (2-12 weeks) 12:
- Sudden onset of irritability, lethargy, seizures, or altered consciousness (intracranial hemorrhage)
- Bulging fontanelle, vomiting
- Skin ecchymoses or petechiae
- Gastrointestinal bleeding
- Exclusively breastfed infant, often with unrecognized cholestasis (pale stools, dark urine, jaundice)
Older children and hospitalized patients 8:
- Oozing from venipuncture sites, surgical wounds, or mucous membranes
- Gastrointestinal bleeding (hematemesis, melena, hematochezia)
- Hematuria
- Epistaxis
- Easy bruising
- History of prolonged antibiotic use, inadequate nutrition, or malabsorption
- Often misdiagnosed as DIC 8
Detailed Approach to History
Neonatal/infant history 12:
Birth history:
- Gestational age (prematurity increases risk)
- Mode of delivery
- Birth trauma
- Vitamin K prophylaxis given at birth? (dose, route, timing)
Maternal history:
- Medications during pregnancy: anticonvulsants, warfarin, rifampin, isoniazid, cephalosporins
- Maternal bleeding disorders
- Maternal diet (vegetarian/vegan diets may be low in vitamin K)
Feeding history:
- Exclusive breastfeeding vs. formula feeding
- Adequacy of feeding (volume, frequency)
- Any feeding difficulties or vomiting
Stool and urine color:
- Pale/acholic stools suggest cholestasis (biliary atresia, neonatal hepatitis)
- Dark urine suggests cholestasis
- Jaundice beyond 2 weeks of age
Bleeding symptoms:
- Onset and duration
- Sites of bleeding
- Severity (oozing vs. frank hemorrhage)
- Any trauma or procedures preceding bleeding
Neurological symptoms (late VKDB):
- Irritability, lethargy
- Poor feeding
- Vomiting
- Seizures
- Altered consciousness
Older children history 8:
Nutritional history:
- Duration of inadequate oral intake or NPO status
- Dietary restrictions (vegetarian/vegan)
- Symptoms of malabsorption: chronic diarrhea, steatorrhea, failure to thrive
Medication history:
- Antibiotics (type, duration)
- Warfarin or other anticoagulants
- Anticonvulsants
- Mineral oil or other laxatives
Medical history:
- Liver disease
- Cystic fibrosis
- Inflammatory bowel disease
- Celiac disease
- Short bowel syndrome
- Recent surgery
Bleeding history:
- Onset: acute vs. gradual
- Sites: single vs. multiple
- Severity
- Any prior bleeding episodes
Family history:
- Inherited bleeding disorders
- Liver disease
- Cystic fibrosis
Detailed Physical Examination
General assessment 12:
- Vital signs: usually stable unless significant blood loss
- Growth parameters: failure to thrive suggests chronic malabsorption
- Level of consciousness: altered in intracranial hemorrhage
Skin examination 12:
- Ecchymoses: size, location, age (color)
- Petechiae: distribution (localized vs. generalized)
- Jaundice: suggests cholestasis or liver disease
- Pallor: suggests anemia from blood loss
Head and fontanelle (infants) 12:
- Bulging fontanelle: increased intracranial pressure from ICH
- Cephalohematoma: size, fluctuance
- Head circumference: rapid increase suggests ICH
Eyes:
- Scleral icterus
- Subconjunctival hemorrhage
Mucous membranes:
- Gingival bleeding
- Oral petechiae or blood blisters
Abdomen 12:
- Hepatomegaly: liver disease, cholestasis
- Splenomegaly: portal hypertension, hemolysis
- Abdominal distension: intra-abdominal bleeding
- Ascites: liver disease
Umbilical stump (neonates):
- Active bleeding or oozing
- Hematoma formation
Genitourinary:
- Hematuria (gross vs. microscopic)
- Post-circumcision bleeding site
Stool examination:
- Melena (black, tarry stools)
- Hematochezia (bright red blood)
- Acholic (pale) stools: cholestasis
Neurological examination 12:
- Level of consciousness: alert, lethargic, unresponsive
- Tone: hypotonia or hypertonia
- Reflexes: asymmetry suggests focal lesion
- Fontanelle: bulging, tense
- Seizure activity
- Focal neurological deficits
Signs of malabsorption:
- Muscle wasting
- Abdominal distension
- Edema (hypoalbuminemia)
Diagnostic Investigations
Initial Panel (Stat Laboratory Tests) 12, 13, 12:
- Prothrombin time (PT)
- Activated partial thromboplastin time (aPTT)
- Complete blood count (CBC) with platelet count
- Fibrinogen level
- Peripheral blood smear
Comprehensive Panel 13, 12:
- Factor assays: II, VII, IX, X (vitamin K-dependent factors)
- PIVKA-II (proteins induced by vitamin K absence or antagonist-II): most specific test for vitamin K deficiency 13
- D-dimer or fibrin degradation products (FDP): to exclude DIC
- Liver function tests: ALT, AST, bilirubin (total and direct), albumin, alkaline phosphatase
- Gamma-glutamyl transferase (GGT): elevated in cholestasis
- Vitamin K level (if available): plasma phylloquinone level
- Fat-soluble vitamin levels (A, D, E): if malabsorption suspected
- Sweat chloride test: if cystic fibrosis suspected
- Tissue transglutaminase antibodies: if celiac disease suspected
- Abdominal ultrasound: if cholestasis suspected (evaluate biliary tree, liver)
- Head CT or MRI: if intracranial hemorrhage suspected (altered consciousness, bulging fontanelle, seizures)
Expected Abnormal Results in Vitamin K Deficiency 13, 12, 9, 8:
Coagulation studies:
- PT: markedly prolonged (often >20 seconds, INR >2.0)
- aPTT: prolonged (typically less prolonged than PT)
- Platelet count: normal (key distinguishing feature from DIC)
- Fibrinogen: normal (key distinguishing feature from DIC)
- D-dimer/FDP: normal or low (not elevated as in DIC)
Factor assays:
- Factor II (prothrombin): decreased
- Factor VII: markedly decreased (shortest half-life, decreases first)
- Factor IX: decreased
- Factor X: decreased
- Factor V: normal (not vitamin K-dependent; helps distinguish from liver disease)
- Factor VIII: normal (not vitamin K-dependent)
Specific tests:
- PIVKA-II: elevated (>2 ng/mL abnormal; >10 ng/mL strongly suggests vitamin K deficiency) 13
- Vitamin K level: low (<0.2 ng/mL)
Response to vitamin K administration 8:
- PT improves within 6-12 hours (diagnostic and therapeutic)
- PT normalizes within 24-48 hours
- This rapid response is the most practical diagnostic test
Cholestasis workup (if late VKDB):
- Direct (conjugated) bilirubin: elevated (>1 mg/dL or >20% of total)
- GGT: elevated
- Alkaline phosphatase: elevated
- Ultrasound: may show biliary atresia, choledochal cyst
Initial Management
Immediate vitamin K administration is both diagnostic and therapeutic 12, 13, 12.
Vitamin K Dosing 12, 13, 12:
Neonates with bleeding (VKDB):
- Dose: 1 mg IV or IM
- Route: IV preferred if active bleeding (slow infusion over 20-30 minutes to avoid anaphylaxis); IM acceptable if no active bleeding
- Repeat dose: if PT does not improve within 6-12 hours, give additional 1 mg
- Maximum: typically 2-3 doses
Infants and children with bleeding:
- Dose: 1-5 mg IV or IM (or 0.5-1 mg/kg, maximum 10 mg)
- Route: IV preferred if active bleeding (slow infusion over 20-30 minutes)
- Repeat dose: if PT does not improve within 6-12 hours, give additional dose
Severe bleeding or intracranial hemorrhage 12:
- Vitamin K: 1-5 mg IV (depending on age/weight)
- Fresh frozen plasma (FFP): 10-15 mL/kg IV to provide immediate replacement of vitamin K-dependent factors
- FFP works immediately while waiting for vitamin K to take effect (6-12 hours)
- Prothrombin complex concentrate (PCC): if available, 25-50 units/kg IV
- Contains concentrated factors II, VII, IX, X
- More rapid and complete correction than FFP
- Preferred in life-threatening bleeding (especially ICH)
- Packed red blood cells: 10-15 mL/kg if significant anemia (hemoglobin <7 g/dL or symptomatic)
Supportive care:
- Hemodynamic monitoring
- Avoid intramuscular injections (except vitamin K)
- Avoid antiplatelet agents (aspirin, NSAIDs)
- Protect from trauma
Treatment of Underlying Cause 12:
Cholestasis (late VKDB):
- Urgent evaluation for biliary atresia (surgical emergency if present)
- Ursodeoxycholic acid for cholestasis: 10-20 mg/kg/day divided twice daily
- Ongoing vitamin K supplementation: 2.5-5 mg oral daily or 1-2 mg IM weekly until cholestasis resolves
Malabsorption:
- Treat underlying condition (cystic fibrosis: pancreatic enzyme replacement; celiac disease: gluten-free diet)
- Vitamin K supplementation: 2.5-5 mg oral daily or 1-2 mg IM weekly
- Monitor other fat-soluble vitamins (A, D, E)
Antibiotic-associated deficiency:
- Continue antibiotics if medically necessary
- Vitamin K supplementation: 1-5 mg oral or IM weekly during antibiotic course
Ongoing Management
Monitor response to vitamin K 13, 12:
- Repeat PT/aPTT: 6-12 hours after vitamin K administration
- PT should improve by 30-50% within 6-12 hours
- PT should normalize within 24-48 hours
- If PT does not improve, consider:
- Liver disease (factor V will also be low)
- DIC (platelets and fibrinogen will be low, D-dimer elevated)
- Warfarin overdose (requires higher vitamin K doses)
- Malabsorption (may need parenteral vitamin K)
Continued vitamin K supplementation 13:
Cholestatic liver disease:
- Oral: 2.5-5 mg daily (may require higher doses up to 10 mg/day)
- Parenteral (if oral ineffective): 1-2 mg IM weekly or 2-5 mg IV weekly
- Monitor PT monthly
Cystic fibrosis:
- Oral: 2.5-5 mg daily
- Monitor PT every 3-6 months
Short bowel syndrome:
- Parenteral: 1-2 mg IM weekly or include in parenteral nutrition (10 mcg/kg/day for infants, 200 mcg/day for older children) 13
Prolonged antibiotic therapy:
- Oral or IM: 1-5 mg weekly during antibiotic course
Parenteral nutrition 13:
- Preterm and term infants: 10 mcg/kg/day
- Older children: 200 mcg/day
- Ensure vitamin K is included in multivitamin preparation or add separately
Monitoring 13:
- PT/INR: initially weekly, then monthly once stable
- PIVKA-II: if available, useful for monitoring subclinical deficiency (target <2 ng/mL) 13
- Clinical assessment: monitor for new bleeding
Neurodevelopmental follow-up (if intracranial hemorrhage occurred) 12:
- Neuroimaging: repeat head CT/MRI at 1-3 months to assess resolution
- Neurodevelopmental assessment at 6,12, and 24 months
- Early intervention services if developmental delays identified
Prognosis & Follow-Up
Prognosis depends on severity of bleeding and timeliness of treatment 12.
Without intracranial hemorrhage:
- Excellent prognosis with prompt vitamin K administration
- Bleeding typically stops within 6-12 hours
- No long-term sequelae if underlying cause is treated
With intracranial hemorrhage 12:
- Mortality: up to 20% in late VKDB with ICH
- Permanent neurological sequelae: 30-50% of survivors
- Cerebral palsy
- Developmental delay
- Seizure disorder
- Visual or hearing impairment
- Prognosis better if:
- Small hemorrhage
- No intraventricular extension
- Prompt treatment
- No secondary complications (hydrocephalus, herniation)
Follow-up recommendations 12:
Short-term (first 3 months):
- Weekly PT/INR for first 2-4 weeks after treatment
- Continue vitamin K supplementation if underlying cause persists
- Monitor for recurrent bleeding
- If ICH occurred: repeat neuroimaging at 1-3 months
Long-term:
- Cholestatic liver disease: monthly PT/INR, ongoing vitamin K supplementation until cholestasis resolves
- Malabsorption syndromes: every 3-6 months PT/INR, ongoing vitamin K supplementation
- Neurodevelopmental follow-up if ICH occurred: assessments at 6,12,24 months and school age
- Educate family on signs of bleeding and importance of vitamin K supplementation
Prevention
Neonatal vitamin K prophylaxis is the most effective prevention strategy 12.
Universal Newborn Prophylaxis 12:
Intramuscular (IM) route (preferred):
- Dose: 1 mg IM within 1 hour of birth
- Efficacy: reduces VKDB incidence from 0.25-1.7% to <0.01%
- Advantages: single dose, highly effective, ensures compliance
- Disadvantages: painful, parental concerns about IM injection
Oral route (alternative):
- Regimen 1: 2 mg oral at birth, at 4-6 days, and at 4-6 weeks 12
- Regimen 2: 2 mg oral at birth, then 1 mg weekly for 3 months 12
- Efficacy: less effective than IM (late VKDB incidence 1.4-6.4 per 100,000 vs. <0.1 per 100,000 with IM)
- Advantages: non-invasive, acceptable to some parents who refuse IM
- Disadvantages: requires multiple doses, compliance issues, less effective
Recommendation: IM administration is the preferred route 12.
High-Risk Newborns 12, 13:
Maternal medications (early VKDB prevention):
- If mother taking anticonvulsants, warfarin, rifampin, or isoniazid:
- Maternal supplementation: 10-20 mg oral vitamin K daily during last month of pregnancy
- Newborn: 1 mg IM at birth (standard dose)
- Consider: additional 1 mg IM at 24 hours if high risk
Cholestasis (late VKDB prevention):
- Screen all infants with prolonged jaundice (>2 weeks) for cholestasis (direct bilirubin, GGT)
- Pale stools or dark urine: urgent evaluation for biliary atresia
- Vitamin K supplementation: 2.5-5 mg oral daily or 1-2 mg IM weekly until cholestasis resolves
Exclusively breastfed infants:
- Ensure vitamin K prophylaxis at birth
- If oral regimen used, ensure compliance with all doses
- Educate parents on signs of late VKDB (irritability, lethargy, seizures, bleeding)
Older Children and Hospitalized Patients 8:
Prophylactic vitamin K supplementation indicated for 13, 8:
Prolonged inadequate intake:
- NPO >5-7 days without vitamin K supplementation
- Dose: 1-5 mg oral or IM weekly
Prolonged antibiotic therapy (>7-10 days):
- Especially broad-spectrum antibiotics or cephalosporins
- Dose: 1-5 mg oral or IM weekly during antibiotic course
Malabsorption syndromes:
- Cystic fibrosis, celiac disease, inflammatory bowel disease, short bowel syndrome
- Dose: 2.5-5 mg oral daily or 1-2 mg IM weekly
- Monitor PT every 3-6 months
Cholestatic liver disease:
- Dose: 2.5-5 mg oral daily or 1-2 mg IM weekly
- Monitor PT monthly
Parenteral nutrition 13:
- Ensure vitamin K is included in PN formulation
- Dose: 10 mcg/kg/day for infants, 200 mcg/day for older children
Critically ill patients:
- Consider prophylactic vitamin K 1-5 mg weekly if multiple risk factors (inadequate intake + antibiotics + liver disease)
Education 12:
Parents of newborns:
- Importance of vitamin K prophylaxis at birth
- Signs of VKDB: bleeding, irritability, lethargy, seizures
- Importance of follow-up if oral regimen chosen
Parents of children with malabsorption:
- Importance of ongoing vitamin K supplementation
- Signs of bleeding
- Medication compliance
Healthcare providers:
- Recognize vitamin K deficiency in hospitalized patients (often misdiagnosed as DIC) 8
- Prophylactic supplementation for high-risk patients
- Avoid unnecessary coagulation studies if vitamin K deficiency suspected; give vitamin K and reassess